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This commentary grows out of an interdisciplinary workshop focused on controversies surrounding the diagnosis
and treatment of bipolar disorder (BP) in children. Although debate about the occurrence and frequency of BP in
children is more than 50 years old, it increased in the mid 1990s when researchers adapted the DSM account of
bipolar symptoms to diagnose children. We offer a brief history of the debate from the mid 90s through the pre-
sent, ending with current efforts to distinguish between a small number of children whose behaviors closely fit
DSM criteria for BP, and a significantly larger number of children who have been receiving a BP diagnosis but
whose behaviors do not closely fit those criteria. We agree with one emerging approach, which gives part or all of
that larger number of children a new diagnosis called Severe Mood Dysregulation or Temper Dysregulation Disor-
der with Dysphoria.
Three major concerns arose about interpreting the DSM criteria more loosely in children than in adults. If clinicians
offer a treatment for disorder A, but the patient has disorder B, treatment may be compromised. Because DSM’s
diagnostic labels are meant to facilitate research, when they are applied inconsistently, such research is compro-
mised. And because BP has a strong genetic component, the label can distract attention from the family or social
context.
Once a BP diagnosis is made, concerns remain regarding the primary, pharmacological mode of treatment: data
supporting the efficacy of the often complex regimens are weak and side effects can be significant. However, more
than is widely appreciated, data do support the efficacy of the psychosocial treatments that should accompany
pharmacotherapy. Physicians, educators, and families should adopt a multimodal approach, which focuses as much
on the child’s context as on her body. If physicians are to fulfill their ethical obligation to facilitate truly informed
consent, they must be forthcoming with families about the relevant uncertainties and complexities.
Introduction
In September 2007, a group of researchers made head-
lines when they reported a forty-fold increase in the
number of office visits in which children had a diagnosis
of bipolar disorder (BP)[1]. The researchers estimated
that whereas, in 1994-1995, in about 25 out of every
100,000 visits a child had a bipolar diagnosis, the num-
ber increased to 1,003 per 100,000 by 2002-2003. During
the same ten-year period, office visits by adults with a
BP diagnosis almost doubled from 905 to 1,679 per
100,000 annually, suggesting that BP diagnoses reported
by community-based clinicians have increased across
the age span. But the very low base rate of this diagnosis
in youth coupled with a rapid rise signaled a major
practice change.
Once thought rare in pre-adolescents, BP is now
increasingly diagnosed in children, including preschoo-
lers [2]. The drugs used to treat it include mood stabili-
zers and antipsychotics [3], which carry the risk of
significant side effects. Perhaps even more than the
diagnosis and treatment of Attention-Deficit/Hyperactiv-
ity Disorder (ADHD) and childhood depression before
it, the ascension of the BP diagnosis in children and its
treatment with medications whose risk/benefit profiles
are inadequately established have generated debate in
both lay and professional communities.
This commentary grows out of a workshop that
explored the debates regarding the increase of BP diag-
noses in children under 17. The workshop was the third
of five in a series aimed at exploring the controversies
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behavioral disturbances in children; the workshop was
highly interdisciplinary, including child psychiatrists,
psychologists, philosophers, sociologists, anthropologists,
and others. Our first commentary, which grew out of
our first workshop, explored the debates in general [4].
Our second commentary explained why informed peo-
ple can disagree about ADHD diagnosis and treatment;
we explored the “zone of ambiguity” between those chil-
dren who clearly do–and those who clearly do not–have
ADHD and the complexities of identifying and imple-
menting effective treatment [5]. In this commentary, we
focus on the intense and complex debate among child
psychiatrists and psychologists about how best to con-
ceptualize the serious emotional and behavioral distur-
bances exhibited by the group of children currently
receiving a BP diagnosis.
This series of workshops was funded by a National
Institute of Mental Health (NIMH) grant to The Hast-
ings Center, which is an independent, nonprofit, non-
partisan, bioethics research institute. The authors of this
commentary are scholars at The Hastings Center. One
of us has a background in philosophical bioethics (EP)
and the other a background in law and bioethics (JJ).
Because neither of us has training in psychiatry, we
relied on the generous advice of child psychiatrist Dr.
Benedetto Vitiello at NIMH and former NIMH director
Dr. Steven Hyman, who helped us identify a wide range
of views within child psychiatry and psychology. We
also relied on the generous advice of anthropologist Dr.
Sarah Harkness to help identify individuals who study
how social and cultural context can affect the interpre-
tation of children’se m o t i o n sa n db e h a v i o r s .A l m o s t
without exception, the experts we invited to the work-
shop accepted, even though we were able to offer only a
very modest honorarium. We held the workshop, con-
sisting of presentations and lengthy follow-up conversa-
tions, in New York City on April 24-25, 2008. (For
more on our method, see [4]). None of our advisors or
workshop members, listed at the end of this commentary,
bears any responsibility for its contents. This is not a
consensus document.
Our primary aim in this commentary is to fairly
describe the debates that occurred at the workshop. As
part of our effort to be as accurate as possible, we will
sometimes include workshop participants’ exact words.
Based on our analysis of the presentations and discus-
sion at the workshop, as well as our reading in the
professional literature, we conclude that the proposed
new diagnosis of SMD, on which the Diagnostic and
Statistical Manual (DSM) V’sp r o p o s e dd i a g n o s i so f
Temper Dysregulation Disorder with Dysphoria (TDD)
is based, may help to clarify the debate about a
troubled group of children who are currently receiving
a BP diagnosis but do not neatly fit DSM IV criteria.
We will suggest that, though in the US a BP diagnosis
can get children the treatment, school accommoda-
tions, and insurance reimbursements they desperately
need and deserve, if applied too widely it can do more
harm than good.
Disagreement about labels, but agreement that these
children desperately need help
Some researchers, physicians, and parents argue that the
sharp increase in rates of BP diagnosis simply reflects
overdue recognition of this disorder in children. As
workshop participant and patient advocate Susan Resko
urged us to remember, a 40-fold increase sounds like a
lot until one recalls the raw percentages: from the BP
diagnosis being present in 0.025% of office visits in 1994
to it being present in approximately 1.0% of the visits in
2003. Moreover, these percentages refer to a clinic sam-
ple, not the community at large.
Those who are not alarmed by the increase suggest
that in the past clinicians missed cases of BP because
they did not understand that it can affect children and
because BP symptoms can look different in children and
adults. As child psychiatrist David Axelson asked, “if it
is possible for children to suffer from anxiety, depres-
sion and other disorders experienced by adults, why not
BP?” Moreover, they emphasize that, untreated, these
children risk school failure, rejection by peers, physical
injury, substance abuse, and even suicide–and their
families can be torn apart.
Others at the workshop argued that BP in children is
poorly defined, which can lead to misdiagnosis and
inappropriate treatment. While children can have BP,
they maintain that it is extremely rare and that when it
is present the symptoms are very like those observed in
adults. The recent increase in BP diagnoses in children
is due to a redefinition of mania, key to BP diagnosis.
Critics of this development hold that children are now
receiving the BP diagnosis instead of one or more of the
diagnoses they might have received in the past (e.g.,
ADHD, oppositional defiant disorder [ODD], and con-
duct disorder [CD], learning disorders, and pervasive
developmental disorders [PDD])–or instead of some
altogether new diagnosis (e.g., SMD). Some critics sug-
gested that the BP diagnosis can be more palatable to
some parents, teachers, and physicians than other bet-
ter-fitting diagnoses, because the BP label attributes the
child’s problematic moods and behaviors to what is per-
ceived to be a context-independent, genetic disorder.
Such critics suggest that the publication in 2000 of The
Bipolar Child by Dimitri and Janice Papolos [6] and a
2002 Time magazine cover story [7] precipitated a surge
of parents asking physicians to give their troubled chil-
dren the BP diagnosis.
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to treat BP. They observe that these drugs may not help
the child, may cause harmful side effects, and increase
the risk that other measures will be overlooked. Work-
shop participant and child psychiatrist Mary Burke
speculated that, in the underprivileged community
where she practices, one of the most effective ways to
help children now receiving the BP diagnosis would be
to promote attachment and reduce stress on families–
stress that falls disproportionately on the poor [8,9].
Consistent with Burke’s point about stress as a possible
precipitant of the symptoms associated with BP and
other diagnoses, is the research of workshop participant
and child psychiatrist Boris Birmaher (and his collea-
gues), which suggests that low socio economic status is
predictive of worse long-term BP outcomes [10].
While there was sometimes deep disagreement at the
workshop about these points and others, there was uni-
versal agreement, including from those child psychia-
trists who have been vocal critics of the way in which
the BP diagnosis has been applied to children, that the
children at issue desperately need help. As child psy-
chiatrist Gabrielle Carlson said, psychiatrists agree that
“there is a group of children with severe irritability or
affective aggression or rages whose explosive behavior is
significantly impairing, that we have been chasing with
different diagnoses over the years, that populate child
psychiatry clinics, and that we haven’t had a great deal
of success in treating.” Regardless of which diagnostic
label is ultimately applied, the children at issue experi-
ence extreme and often debilitating moods and exhibit
deeply problematic behaviors, sometimes including sui-
cidal and homicidal rages.
Clinical reports describe chronically impaired children
who are highly irritable, angry, explosive and dysphoric,
often as their baseline functioning [11-13]. They may
also experience racing thoughts and periods of elation,
grandiosity, hypersexuality, and suicidality [14]. Vivid
portraits of the suffering of children diagnosed with BP
(and of the suffering these children’ss y m p t o m sc a n
cause others) can also be found in some of the more
detailed media reports, including the Time magazine
cover story from 2002 [15] and a 2008 feature by jour-
nalist Jennifer Egan in the magazine section of the New
York Times [16].
Psychiatric diagnoses are of course based on descrip-
tions of clusters of behaviors that everyone in a popula-
tion exhibits to some degree. Human beings, through
our social institutions (in this case medicine), determine
when clusters of these behaviors impair functioning
enough to warrant a disease label. To emphasize the
role of flesh-and-blood humans in reaching those deter-
minations, workshop participant and anthropologist
Emily Martin suggested that we might speak of “living
under the description of” a given psychiatric diagnosis.
Martin herself is diagnosed with BP and, because she
fully acknowledges the very real impact her moods and
behaviors can have on her ability to flourish, she seeks
treatment for the disorder. Moreover, she is keenly
aware that the cluster of behaviors that we call BP has
been recognized for millennia and across cultures. But
in saying that she “lives under the description of bipolar
disorder,” Martin emphasizes the respect in which these
behaviors might have developed somewhat differently,
been interpreted somewhat differently, and responded to
somewhat differently in a different society or time [17].
Noticing the roles of interpretation and values in mak-
ing psychiatric diagnoses should make us less surprised
to see controversies about whether a given set of beha-
viors are bad enough to warrant a diagnosis and about
what “the right” diagnosis is.
There is evidence that the pharmaceutical industry
plays a distressingly large role in shaping those interpre-
tations and values [18-20]. We note in particular the
concern regarding financial conflict of interest recently
raised about some BP researchers. While we share many
of the concerns expressed in lay and academic publica-
tions about financial conflicts of interest and the role of
the pharmaceutical industry in diagnosis development
[21-25], exploration of these debates could not resolve
the important questions regarding diagnosis and treat-
ment of BP that were the focus of our workshop and
are the focus of this commentary.
The rate of BP diagnoses is rising faster in the US than
elsewhere
Though debates about the diagnosis of BP in children
can be traced back to the 1950s [26], and though Gab-
rielle Carlson published “Bipolar affective disorder in
childhood and adolescence” in 1983 [27], the rapid
increase in the number of diagnoses of BP did not begin
in the US until the mid 1990s [1,28] (see Table 1).
While some symptoms now associated with the BP label
can be found in previous versions of the DSM in
descriptions of disorders such as “unsocialized aggres-
sive reaction of childhood,”“ adjustment reaction of
childhood,” and “schizophrenic reaction, childhood
type,” DSM’s description of BP did not in the past and
does not now explicitly address diagnosis of this disor-
der in childhood.
The increase in diagnoses seems to begin with germ-
inal 1994 and 1995 articles by Barbara Geller et al.,
Janet Wozniak et al. and Joseph Biederman et al., which
proposed that BP was more prevalent in children than
previously thought [11,29-31]. When DSM-IV was pub-
lished in 1994, it contained a new section, “Disorders
Usually First Diagnosed in Infancy, Childhood, or Ado-
lescence.” While this section does not specifically
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disorders included in other sections of the manual have
an onset during childhood or adolescence [32].”
Since then, diagnoses of BP in children in the commu-
nity have increased in the US [1,28]. Pre-school-age chil-
dren are now among those receiving this diagnosis [2],
which a short time ago was not thought to exist in early
elementary school age youth (6-9 years) or even in early
adolescence (10-14 years). In addition to calling atten-
tion to the increasing rate of diagnoses in children,
critics have observed that the numbers are higher in the
US than elsewhere and it seems that the US is the only
country where BP is diagnosed in pre-school-age chil-
dren. This situation suggested to workshop participant
and child psychiatrist Jon McClellan (citing Soutullo et
al. [33]) that something is askew in US diagnostic prac-
tices, and not, or not simply, in US genomes or
environments.
While there are not good data comparing prevalence
rates in the general population of children in different
countries, the data comparing clinical populations
(children brought to physicians’ offices) reveal higher
diagnostic rates in the US than many other nations. Psy-
chiatrist and workshop member, Claudia Mehler-Wex,
reported that, whereas 6% to 19% of children and ado-
lescents in US clinical populations are diagnosed with
BP [34-36], the diagnosis is virtually never made in Eng-
land (1.7 cases/100,000/year)[37] nor Ireland (2.2 cases/
100,000/year) [38]. Mehler-Wex reported that countries
like Spain, India, Finland, Denmark, and Germany also
fall well below the diagnostic rates of the US. (Brazil,
where 7.2% of the clinical population is diagnosed with
BP [39], is the only country with diagnostic rates close
to the low end of the estimates for the US).
Mehler-Wex offered several reasons for higher rates of
BP diagnoses in US children. First, DSM IV diagnostic
criteria for BP cast a wider net and capture more
affected individuals than do the International Statistical
Classification of Diseases and Related Health Conditions
10
th Revision (ICD 10) criteria used in Europe. For
example, where DSM IV requires only one episode of
mania, or one episode of depression plus one episode of
Table 1 Timeline: The Recent Debate about BP in Children
Early
1980s
Gabrielle Carlson et al. observe that bipolar symptomatology in preadolescent children can include severe irritability and emotional
lability (as opposed to the classic symptoms that appear in adults and adolescents) [27].
1994 Geller et al. report in Journal of American Academy of Adolescent and Child Psychiatry (JAACAP) conversion to BP in 32% of a sample of
children with major depression [31].
1995 Geller et al. in Journal of Affective Disorders suggested that children and adolescents with rapid-cycling mania characterized by elevated/
expansive and/or grandiose mood have BP; the researchers did not use irritability to characterize BP because it also commonly appears
in ADHD [29].
1995 Wozniak et al. [11] and Biederman et al. [30] in two JAACAP articles report that 16% of a clinical population of children met the criteria
for mania primarily by exhibiting chronically irritable mood and describe their use of the Child Behavior Checklist to confirm their
diagnoses of BP in these children.
1998 Klein et al., critique the move to consider chronic irritability a form of mania [47].
2000 Publication of The Bipolar Child by Demitri and Janice Papolos, a book aimed at parents, whose success coincides with an increase in
visits to doctor’s offices by parents regarding a bipolar diagnosis for their children [6].
2002 Time magazine runs a cover story on children with BP [15].
2003 Leibenluft et al. describe a new syndrome, Severe Mood Dysregulation, (SMD), which aims to bring some conceptual order to the
increasingly heterogeneous class of children receiving a BP diagnosis [28,48,49,51].
2005 Article by Kowatch et al. describing treatment guidelines for children and adolescents with BP published in JAACAP. Accompanying
commentary calls attention to lack of evidence that childhood diagnosis is contiguous with adult BP and critiques some symptoms as
difficult to distinguish from developmentally normal childhood behavior [46].
2006 Brotman et al. use the label Severe Mood Dysregulation in the title of a scientific article, offering a new label for many children now
receiving the BP diagnosis [49].
2007 JAACAP publishes practice parameter for diagnosis and treatment of BP in children and adolescents. Parameter follows Geller et al.
diagnostic criteria more than those proposed by Biederman et al. but warns of difficulty differentiating symptoms from normal
childhood behavior and urges periodic revisions of any diagnosis and treatment plan [57].
2007 Archives of General Psychiatry publishes study reporting a 40-fold increase between 1994 and 2003 in the number of office visits in which
children (0-19) had a diagnosis of BP [1].
2009 Zito et al. report a 10-year trend for Medicaid-insured youth with clinician-reported pediatric bipolar disorder showing a proportional
increase in minority youth with this diagnosis from 1997 to 2006 (23% increase in African-American and other minorities and
corresponding drop in white youth) [85].
Crystal et al. report that poor children are four times more likely than wealthy children to receive atypical antipsychotics [70].
2010 Olfson et. al. report a doubling of the number of privately insured 2-5 year-old children with a psychiatric diagnosis who receive an
antipsychotic, and lament the sparseness of non-pharmacological mental health resources [3].
Authors working on DSM V propose adding new diagnostic category, which is based on Severe Mood Dysregulation and may be called
Temper Dysregulation Disorder with Dysphoria [54].
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one episode of depression plus at least two episodes of
mania [32]. Moreover, according to Mehler-Wex, practi-
tioners in the US use lower thresholds for identifying
symptoms than do their counterparts in Europe. Many
of the children diagnosed with BP in the US would else-
where be diagnosed with hyperkinetic disorder (roughly
the ICD equivalent of ADHD), a different mood disor-
der, or a disruptive behavior disorder.
Another reason offered to explain higher diagnostic
rates is that, as indicated by rates of stimulant and anti-
depressant use, US culture is in general more congenial
than European cultures to psychiatric diagnoses and
their pharmacological treatment in children. If, as psy-
chiatrist Peter Kramer once suggested, the US was a
country of “pharmacological Calvinists,” it no longer
seems to be [40].
On the other hand, workshop participant and child
psychiatrist Joseph Biederman argued that nothing is
“askew.” His explanations for the difference in preva-
lence rates included: that Europeans are biased against
recognizing psychiatric disorders in children; that Eur-
opeans and American reporting practices lead to differ-
ences in prevalence rates that are only apparent; and
that US rates of diagnosis reflect a deeper understanding
of the disorder among US psychiatrists.
Diagnosing psychiatric disorders in children can be
challenging
Before taking a closer look at the debates in the US, we
should recall two reasons that it can be difficult to diag-
nose psychiatric disorders in children. Psychiatric disor-
ders are predictable clusters of emotional, behavioral
and sometimes somatic symptoms that cause impair-
ment and emerge on a spectrum. Bright lines do not
separate individuals whose emotions and behaviors are
and are not disordered enough to receive a BP diagno-
sis. Second, because different diagnoses, some of which
are themselves contested (e.g., CD, ODD, PDD, ADHD,
and BP) can share some of the same symptoms, decid-
ing which diagnostic label(s) to apply to a particular
patient can be challenging.
Moreover, identifying symptoms and making a diagno-
sis can be harder in children than in adults. Younger
persons can have difficulty noticing and describing
symptoms and providing accurate accounts of time of
onset and duration of symptoms (although children
always have a secondary informant). Further, given how
rapidly children’s brains develop, even practitioners can
and do disagree about whether a given behavior or
mood is developmentally appropriate or a symptom of
disorder. Is, for example, a 4-year-old’s claim that she is
superwoman a sign of imagination, self-confidence, or
grandiosity? If a child accompanies her claim to be
superwoman with a clear indication that she is about to
jump from a hotel balcony, there is good reason to infer
the presence of a symptom. Other times the answer will
be less obvious.
In children and in adults, it can be tempting to con-
clude that a given medication’s ability to reduce a parti-
cular symptom confirms a diagnosis, but it does not.
Gabrielle Carlson offered the example of the atypical
antipsychotic risperidone (Risperdal), which is effective
at reducing aggression or rages in children diagnosed
with BP–but is also effective in reducing aggression or
rages in children with one or more disruptive behavior
disorders (ADHD, ODD, and/or CD) and below average
intelligence [41] as well as in children with autism [42].
Carlson suggested that atypical antipsychotics reduce
rages the way aspirin reduces fever: “Regardless of
whether the underlying cause is viral or bacterial, aspirin
will reduce fever. But if the patient has a bacterial illness
and the aspirin masks the symptoms temporarily, you’ll
think you’ve treated something you haven’t. The patient
won’t get the antibiotic she needs.”
The DSM IV view of the BP spectrum
DSM-IV lists four BP subtypes: BP-I, BP-II, Cyclothymic
Disorder, and BP-NOS [32]. In adults, the bar to getting
t h eB P - Id i a g n o s i si ss e tf a i r l yh i g ha n dt h ec l a s s i c
symptoms of mania (even when mixed with depressive
symptoms) are relatively easy for a well trained physi-
cian to identify. Much of the disagreement about diag-
nosing BP in children, however, revolves around
determining just what mania looks like in children.
According to DSM IV, a full-blown Manic Episode
entails “a distinct period of abnormally and persistently
elevated, expansive, or irritable mood” lasting for at
least 1 week. The central question in the pediatric
debate is whether this episodicity criterion should be
altered to include children who exhibit chronic irritabil-
ity or cycle very rapidly between elevated mood and
euthymia or depression. Under DSM, to meet the cri-
teria for mania, when the patient’sm o o di selevated or
expansive she must exhibit at least 3 of the following 7
symptoms: grandiosity, decreased need for sleep, pres-
sure to keep talking, flight of ideas, distractibility,
increased goal-directed activity, or excessive involvement
in pleasurable activities that have a high potential for
painful consequences. Alternatively, to meet the criteria
for mania, when the patient presents with irritability,
she must exhibit at least 4 of those 7 symptoms.
DSM sets the bar for BP-II lower in the sense that one
does not need a full-blown Manic (or Mixed) Episode;
having one or more episodes of Major Depression accom-
panied by at least one hypomanic episode suffices. (In
hypomania the symptoms are the same as in mania, but
their duration is shorter–4 days instead of 1 week–and
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mic Disorder because one only needs numerous periods of
hypomanic symptoms and periods of depressive symptoms
that do not meet criteria for Major Depressive Disorder.
The Cyclothymic Disorder label, however, is rarely applied
to adults or children. Finally, to receive the BP-NOS diag-
nosis, one does not need to meet the criteria for any of the
preceding 3 subtypes of BP. For example, one may have an
abnormal mood, constituted by a rapid alteration between
manic and depressive symptoms, but those symptoms do
not meet the minimal duration criteria for a Manic Epi-
sode or Major Depressive Episode.
Workshop discussion and debate focused not on diag-
nosis of those rare children who exhibit discrete epi-
sodes of mania and meet full DSM criteria for BP-I, but
on whether the majority of the children described by
researchers like Geller et al. and Biederman et al. were
best captured by the BP label or by some other diagno-
sis. Child psychiatrists’ thinking about these difficult-to-
diagnose children has evolved in, very roughly speaking,
three stages since 1994.
Stage 1: Expanding the definition of BP
Geller et al., Wozniak et al., and Biederman et al., were
n o tt h ef i r s tt oc h a l l e n g et h ev i e wt h a tm a n i ai sr a r ei n
children, but their 1994 and 1995 papers have proved
highly influential.
In 1994, Geller et al. reported that 32% of a sample of
79 children diagnosed with major depression had con-
verted to BP-I or BP-II when followed over a 2-5 year
period [31]. The following year, Geller et al. reported
diagnosing 26 children aged 7-18 years with BP using a
semi-structured diagnostic interview instrument [29].
They sought to define BP in a way that would allow
them to cleanly distinguish it from ADHD: because one
of the cardinal symptoms of mania–irritability–is also a
symptom of ADHD, they would not give a BP diagnosis
to children who exhibited only irritability. On their
approach, for mania to be present (and for a BP diagno-
sis to be made), children had to exhibit elevated or
expansive mood or be grandiose. Crucially, they also
maintained that manic and hypomanic symptoms look
different in children than in adults. Specifically, they
modified DSM’s criteria to allow a diagnosis of mania in
children who rapidly cycled from mania or hypomania
to euthymia or depression, including those who
switched moods in the course of a day, and those whose
symptoms did not have onset at the same time [29].
(Barbara Geller declined to participate in our workshop.)
At about the same time as Geller et al., were expand-
ing or reinterpreting the DSM account of a manic epi-
sode characterized by elevated mood, Biederman et al.
and Wozniak et al. were expanding or reinterpreting the
DSM account of a manic episode characterized by
irritability. In two 1995 papers, Wozniak et al. and Bie-
derman et al. determined that 16% of their clinical
population met the criteria for BP (they did not specify
which BP subtype they observed)[11] primarily because
of chronic irritability. They then argued that children
who, based on a time-consuming structured interview,
fully satisfied their understanding of DSM III criteria for
mania, could also be identified with a relatively simple,
cheap, easy-to-use symptom checklist, the Child Beha-
vior Checklist (CBCL) [30]. While acknowledging the
limitations of their study and the need for more
research, Biederman et al. argued that, because “the clin-
ical picture of pre-adolescent mania is very severe and
impairing, there is a pressing need to refine our methods
of diagnosing mania in such children (ital. added) [30].”
(Critics of Geller’s approach observe that 97.9% of the
sample she reported in 1995 paper also exhibited irrita-
ble mood and that her later studies found rampant irrit-
ability in her sample [35,43], raising questions about
whether Geller et al. and Biederman et al. are really
observing different symptoms or are simply using differ-
ent terms to arrive at the same diagnosis.)
To support his group’s refined or expanded under-
standing of childhood mania, Biederman (citing Perlis et
al. [44]) observed at our workshop that about 65% of BP
adults report having BP symptoms as children or adoles-
cents that were missed by their physicians. He therefore
infers that BP symptoms can look different in children,
and that clinicians can miss pediatric mania if they are
looking for the classic adult presentation.
Many workshop members were not persuaded by
either expanded conception of mania. Aside from con-
cerns about reinterpreting the episodicity requirement,
there were also concerns about whether the observed
irritable or elevated moods were properly understood as
symptoms of BP. Jon McClellan, for example, was criti-
cal of what was being counted as grandiosity, noting
that “Normal children display numerous behaviors and
beliefs that would be considered pathological by adult
standards [45].” He also suggested that many of the chil-
dren Biederman et al. diagnose with BP are just “moody
kids with rage outbursts and aggression.” Gabrielle Carl-
son observed that “euphoria is easy to find if you’re
hunting for it, and if you infer it from merely being
silly"–as one could given some of the language in the
2005 treatment guidelines for BP in JAACAP [46]. She
did, however, acknowledge that episodic euphoria–
euphoria that represents a dramatic shift from that
child’s usual mood and that appears with other symp-
toms–may be easier to identify.
Biederman, however, argued that in its intensity, fre-
quency, and association with “out-of-control aggressive
behavior,” the irritability associated with BP is “qualita-
tively distinct” from the irritability associated with other
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that, much like a neurologist can determine the differ-
ence between a seizure associated with petit mal and
one associated with temporal lobe epilepsy, so can a
properly trained child psychiatrist distinguish between
the different types of irritability associated with different
diagnoses.
Rachel Klein argued, as she had in JAACAP in 1998,
that it is a mistake to interpret chronic irritability as
mania [47]. For irritability or elevated mood to count as
a symptom of BP, it must appear in distinct and sus-
tained episodes–not as chronic or rapidly cycling. As
Klein put it, episodicity is a sine qua non of BP.
Stage 2. Tightening the definition of BP and beginning
to define a new diagnosis
In the early 2000s, some researchers began to speak of a
BP spectrum, stretching from Narrow Phenotype BP to
Broad Phenotype BP. Narrow Phenotype children were
largely synonymous with strictly defined BP-I patients.
In 2003 Ellen Leibenluft et al., described the Broad Phe-
notype children:
Children exhibiting the broad phenotype may ulti-
mately prove to be a heterogeneous group. Some
m a ye v e n t u a l l ym e e tt h es t r i c tc r i t e r i af o r( h y p o )
m a n i a ;t h ec o u r s eo fo t h e r s ’ illness may be consis-
tent with dysthymia, major depressive disorder, or
some form of disruptive behavior disorder; and still
o t h e r sm a yp r o v et oh a v eas y n d r o m et h a ti sn o t
well captured by the current diagnostic system [48].
That is, while there was a small group of children who
did warrant the Narrow Phenotype BP (or BP I) label,
there was a larger group that would be better be captured
under the rubric of Broad Phenotype BP. Some of the
children in that latter, heterogeneous group might some-
day exhibit BP I, some might be conceptualized as exhi-
biting depression or a disruptive behavior disorder–and
some might best be conceptualized as having a disorder
that was not articulated in DSM IV. That is, Leibenluft et
al. were suggesting that some children who had been
receiving a BP diagnosis might be better served by a new
diagnosis, perhaps called Severe Mood Dysregulation (or,
as the DSM V editors are currently proposing, “Temper
Dysregulation Disorder with Dysphoria”) [39].
Stage 3: Severe Mood Dysregulation category
gains support
As others became familiar with the SMD label, and as
the data showing differences between SMD and BD
grew stronger, Leibenluft et al. largely dropped the
Broad Phenotype BP label. In 2006, SMD appeared for
the first time in the title of a scientific article [49],
describing a group of children who share severe irritabil-
ity and hyperarousal symptoms with BP I children, but
who exhibit chronic irritability and do not share the hall-
mark elevated mood or grandiosity required by the DSM
diagnosis of BP I. These children were said to exhibit
developmentally inappropriate reactivity to negative
emotional stimuli, such as “outbursts characterized by
yelling and/or aggression [28],” which occur at least
3 times a week, and are impairing in at least 2 settings
(home, school, peers). To receive the SMD syndrome
label, children must experience symptoms for at least a
year without more than 2 symptom-free months. Onset
begins before age 12 (according to Leibenluft et al.’s
data, average age of onset is 5.1 years) (personal com-
munication). A prevalence study by Brotman et al.
found that SMD is relatively common in children, with
a prevalence rate of 3.3% [49].
Children with SMD also exhibit ADHD- and mania-
like symptoms, including 3 of the following: insomnia,
intrusiveness, pressured speech, flight of ideas/racing
thoughts, distractibility, and psychomotor agitation [28].
B u tt h es e v e r i t yo ft h ei r r i t a b i l i t ya n dt h ei n t e n s i t yo f
mood/anxiety symptoms are greater in youths with
SMD than the average child receiving the ODD and
ADHD diagnoses. Moreover, the ADHD plus ODD
diagnosis fails to capture the mood and anxiety symp-
toms that characterize SMD youths.
At our workshop, Leibenluft began to sketch the
argument that SMD meets the Robins and Guze cri-
teria for a valid diagnosis [50]. SMD children are at
significantly increased risk for developing depression–
not BP–at age 18 [49]. These children are less likely to
have parents with BP than are children with BP [51].
When playing frustrating games, the brains of children
with SMD and BP respond differently (as measured by
EEG) [52]. A new study by Brotman, Leibenluft, and
others, using fMRI, finds that children who have
received the BP, SMD, and ADHD diagnoses exhibit
unique neural correlates in emotion processing of neu-
tral faces [53].
Some challenges were put to Leibenluft at the work-
shop. Biederman argued that no new nosological entity
is needed because the ADHD and ODD diagnoses
together adequately capture the children Leibenluft
et al. are classifying as SMD. Sociologist Ilina Singh
asked if part of Leibenluft’s argument was circular
because, by invoking emerging neuroimaging data pur-
porting to show that the brains of children with SMD
and BP function differently [28], the assumption is made
that we already know just what we are trying to figure
out: what SMD is. Leibenluft responded pragmatically:
“You have to start somewhere. Start with observation,
test, now look at brains, refine categories. It’sa ni t e r a -
tive process”
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about children with the constellation of symptoms at
issue, believes that, in addition to recognizing the differ-
ence between SMD (or BP, for that matter) and ADHD,
physicians also need to recognize the possibility that
children who receive one of those diagnoses might actu-
ally have a learning disorder or a PDD spectrum disor-
der. Such children, Carlson argued, exhibit the sorts of
aggressive rages that Leibenluft links with SMD (and
that Biederman links with BP). While largely agreeing
with Leibenluft et al., Carlson was stressing how easy it
is to miss a learning disorder or a PDD spectrum disor-
der, among others. In a similar vein, Mary Burke voiced
the concern that some children diagnosed with BP
might more helpfully be diagnosed with PTSD or what
she calls “parent-child relationship disturbance” (PCRD),
which in her clinical experience are often overlooked.
We recognize the magnitude of the contributions
made by Biederman et al. and Geller et al.: with their
research they have brought much needed attention to a
group of deeply troubled children. “Diagnostically home-
less children,” as Carlson calls them, can be very diffi-
cult to help and to get help for from educational,
medical and other support systems. Because of the way
mental health and special education services are cur-
rently funded in the US, an ill-fitting diagnosis can be
more helpful than no diagnosis in securing services
(such as hospitalization and prescription medications) as
well as disability status and other support services.
Researchers, too, usually need a DSM diagnosis if they
hope to find funding for their research. (We note,
though, that NIMH is keenly aware of, and attempting
to help researchers deal with, the ramifications of this
nosological debate.) Despite these pragmatic concerns,
however, we were persuaded that departing from a nar-
row interpretation of the DSM criteria risks confusing
the discussion about the nature of the mood and beha-
vioral problems suffered by the children at issue. We
believe that a new diagnosis, along the lines of SMD,
could prove more helpful to children, families, physi-
cians and researchers. Indeed, it was recently announced
that either SMD or TDD is being considered for inclu-
sion in DSM V [54].
Why does the diagnostic label matter?
Overall treatment recommendations, monitoring, and
prognosis can be different for a child diagnosed with BP
and a child diagnosed with, say, ADHD, a learning dis-
ability, or PTSD. However, because the medications
used to treat these different diagnoses can also be the
same, one might ask: what difference does it make
which diagnosis a child receives?
Gabrielle Carlson responded that even if many of the
same medications are prescribed for BP and some of its
diagnostic cousins, the overall treatment plans and prog-
noses for the children are different. For example, stimu-
lants can trigger mania in people with BP [55], and
there is evidence that antidepressants can also [56].
Conversely, children who actually have ADHD, depres-
sion, or anxiety and who are treated with the standard
BP medications may experience the side effects of those
medications and not improve. Moreover, because DSM’s
diagnostic labels are meant to facilitate research, apply-
ing them inconsistently can compromise it [57].
As Carlson also emphasized, focusing on BP can
“blind clinicians to the fact that there are other things
they might be focusing on.” That is, because BP is asso-
ciated with high heritability estimates and is treated pri-
marily with medications, physicians may (erroneously)
infer that psychosocial treatments will not be helpful, or
may be less inclined to delve deeply into the quality of
the child’s home environment or family relations.
Complexities surrounding pharmacological treatment
As indicated by the 2007 practice parameter that
appeared in JAACAP, the first mode of treatment for
children with strictly-defined mania is a combination of
drugs, including traditional mood stabilizers such as
lithium, anticonvulsant mood stabilizers such as dival-
proex (Depakote) and carbamazepine (Tegretol), and the
newer, “atypical” antipsychotics such as olanzapine
(Zyprexa), quetiapine (Seroquel), and risperidone (Ris-
perdal). However, there are virtually no published
research studies evaluating either the long-term (i.e.,
longer than 6 months) effectiveness or the safety of
these pharmacological combinations. Support for their
use is based on studies of individual medications or, in
rare instances, on adjunctive treatment.
Moreover, according to some workshop participants,
the efficacy of some individual medications used to treat
children with BP is either unimpressive or not yet ade-
quately established. Workshop participants Gabrielle
Carlson and Julie Zito assessed the data on the efficacy
of the mood stabilizers lithium, divalproex, and carba-
mazepine in treating children as “weak.” That is,
response rate (the ability to reduce symptoms of mania
by 50%) in these medications did not beat placebo.
Response rates for atypical antipsychotics show a better,
60-80% response with monotherapy for treatment of
acute mania or mixed episodes compared to about a
25% response to placebo [58].
As the authors of the 2007 JAACAP practice para-
meter lament, due to limited studies in youth, “most of
the treatment recommendations for early-onset BP are
d e r i v e df r o mt h ea d u l tl i t e r a t u r e[ 5 9 ] . ” Of the 18 or so
medications routinely prescribed for the treatment of
BP, the FDA has approved only four for use in children,
specifically: lithium for children over 12 years old,
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children over 10, and haloperidol (Haldol) for children
over 3. (In addition, an advisory panel to the FDA
recently recommended approval of quetiapine [Seroquel]
and olanzapine [Zyprexa] for children over 13 years,
although official FDA approval has not yet been made.)
All other medications are used off label, including when
approved medications are used to treat children younger
than the specified age limits. While off-label use of med-
ications is common in medicine, including in children, it
is far from ideal. Experience with other medications has
shown that because children are physiologically different
from adults, medications that are generally safe and
effective in adults are sometimes unsafe or ineffective in
children [61-63].
Because many children with BP can also have another
diagnosis (or diagnoses) such as ADHD, depression,
anxiety, ODD, or OCD, additional medications may be
added to the drug regimen, including antidepressants,
stimulants, and first-generation antipsychotics such as
haloperidol (Haldol) and chlorpromazine (Thorazine).
And because every medication can have side effects, still
more medications can be added to the regimen to treat
the side effects.
The side-effects problem is as worrisome as it is famil-
iar. Atypical antipsychotics are associated with extreme
restlessness, uncontrollable speech and involuntary
movements, and to a lesser degree tardive dyskinesia as
well as drowsiness, increased metabolic problems, and
significant weight gain [64-66]. The latter side effect cre-
ates additional risks, including juvenile diabetes and high
cholesterol [57]. Mood stabilizers such as lithium and
anticonvulsants also carry the risk of significant weight
gain, drowsiness, and decreased cognition, as well as the
development of tremors. Many of these medications
carry risks to fetuses, leading the JAACAP practice para-
meter to recommend that clinicians perform adjunctive
pregnancy tests and specifically warn female patients
and their families about concerns regarding the anticon-
vulsant valproate and polycystic ovary disease [57,67,68].
Pharmacoepidemiologist Julie Zito pointed out that,
while the complicated and difficult symptoms associated
with BP call for complex treatment regimens, we know
that, as a general rule, “the larger the number of medica-
tions used to treat a condition, the greater the risk of
adverse events [69].” Yet, as Mary Burke suggested,
“treatment guidelines support polypharmacy,” as do the
realities of clinical practice. “If you only have 20 minutes
a month [with a child]” she argued, “it is easy to add a
second antipsychotic.” Joseph Biederman, however,
offered reasons to explain and defend polypharmacy,
including: children with BP often also have other disor-
ders and therefore require more than one medication;
one drug alone may not be as effective as that drug in
combination with an additional drug(s); and additional
drugs are sometimes needed to treat side effects of
another effective but poorly tolerated medication.
As the number of BP diagnoses in children has
increased, so has the number of prescriptions in at least
two of the drug classes listed above: anticonvulsants and
atypical antipsychotics. In a 2009 article in Health
Affairs, Stephen Crystal et al. describe not only sparse
data regarding the efficacy of the newer or “atypical”
antipsychotics and plentiful data regarding their meta-
bolic risks, but they also describe a trend whereby low-
income American children are as much as four times
more likely than higher-income children to receive aty-
pical antipsychotics (for BP and other psychiatric diag-
noses) [70]. As Crystal et al. also say, however, no one
knows at this point why poor children receive treatment
with antipsychotics at such a high rate. One possible
explanation has to do with social control, or an unwill-
ingness to invest in costly non-pharmacological
a p p r o a c h e sf o rp o o rc h i l d r e n .A n o t h e re x p l a n a t i o n
would observe that because poorer children are sub-
jected to greater stress than wealthier children, their
symptomatology may be worse [71], which may make
more intensive pharmacotherapy appropriate.
Julie Zito presented community-based population data
at the workshop showing between 2- and nearly 6-fold
increases in the use of anticonvulsants by children aged
0-19 years across a 10-year period [72]. Anticonvulsants
of course also have non-psychiatric uses, but in one
study Zito and colleagues reported that 81% of youth
who received an anticonvulsant-mood stabilizer were
prescribed it for a psychiatric diagnosis and only 19%
had a seizure-related diagnosis [73].
Zito also presented demographic data showing that
children taking anticonvulsants are increasingly under
13 years old, male, and African American (14% in 2004-
2005 compared with 6% in 1996-1997) [74]. The same
data show that 50% of the children taking anticonvul-
sants have a BP diagnosis, and that 38% received a sti-
mulant, 40% an antipsychotic, 52% an antidepressant,
and 12% another psychotropic medication (including
lithium) in addition to the anticonvulsant. Zito et al.
found that in 2004/2005 pediatricians and other non-
psychiatry specialists wrote a larger proportion of antic-
onvulsant-mood stabilizer prescriptions for youth with
psychiatric diagnosis than in the previous decade [75].
When Gabrielle Carlson asked the deceptively simply
question, “Do we know if, after taking these drugs, these
kids are better off?” Julie Zito answered, “We have little
data on the effectiveness of treatment in community
populations. I can tell you about risks from some post-
marketing systems, e.g. the FDA Adverse Event Report-
ing System, but there is insufficient evidence of benefits
in community-treated populations.” Zito herself then
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developing the infrastructure, design and measurement
protocols to provide the benefit and risk information we
need to assess medication outcome in community popu-
lations [76]?”
Of course, against the potential side effects and the less-
than-ideal efficacy of these agents must be weighed the
risks of not treating children with prescription medica-
tions. When a child’s moods and behaviors are causing
her significant distress and are impairing her ability to
learn, develop friendships, and participate in family life,
physicians and parents may decide that medication treat-
ment is the only, or is an important, way to stabilize the
child so that her well-being can be preserved or addressed
through psychosocial or educational interventions. Many
workshop participants, including those critical of current
prescribing practices for BP, agreed that there are times
when not medicating a child carries serious risks.
Our goal here is not to assess the validity of the evi-
dence for any drug or treatment approach. Instead we
seek simply to emphasize that the facts are not as com-
plete as families and physicians would wish them to be.
Prescribing medication is always a balancing act, with
physicians and parents weighing what is known about
the drug’s effectiveness and side effects against the sever-
ity of the symptoms the medication will target. In the
case of the drugs used to treat BP (and related disorders)
the balancing act can be difficult due to a lack of agree-
ment about the diagnosis and a lack of information about
the safety and efficacy of the medications. Physicians and
other mental health care professionals have an ethical
obligation to be honest with parents about these com-
plexities. Policy makers, funders, and researchers have an
ethical obligation to ensure that research is funded and
conducted to fill these knowledge gaps.
Psychosocial treatment
There was agreement at our workshop, as there is in
much of the literature, that medications will often be
the first-line treatment for children diagnosed with BP
or presenting the specific symptoms discussed here.
However, many workshop participants also stressed that
psychosocial treatments can complement pharmacother-
apy, and they lamented a lack of attention to these treat-
ments. Child psychologist David Miklowitz quipped,
“We’re getting to the point where psychosocial treat-
ment is being called non-pharmacological treatment.”
The workshop members who spoke about “non-phar-
macological” treatments spent little time trying to distin-
guish among closely related diagnoses. Instead, they
described different psychosocial interventions, summar-
ized what is known about the effectiveness of these
interventions at changing behavior and assisting children
and families to cope with difficult moods and behaviors,
and described the barriers to greater availability of these
treatments.
David Miklowitz, focused on four psychosocial treat-
ments: family focused treatment (FFT), interpersonal
and social rhythm therapy (IPSRT), Cognitive Behavioral
Therapy (CBT), and psychoeducation. These therapies
were selected in part because they have shown efficacy
in adults with BP. He explained that two or more treat-
ments are often best used in combination because those
that focus on early recognition of prodromal signs and
medication adherence affect mania more than depres-
sion and those that focus on interpersonal coping strate-
gies affect depression more than mania. Miklowitz also
stressed that treatments of three or fewer sessions do
n o tw o r ka sw e l la st r e a t m e n t so ft w e l v eo rm o r e
sessions.
One target of psychosocial therapies is stress manage-
ment, because stress and trauma are both contributing
causes to and results of manic episodes. Psychologist
Mary Fristad emphasized environmental precipitants of
mania, stressing what she labeled bi-directional causa-
tion. “If you have mania” she explained, “then you create
a lot of trauma in your life and trauma precipitates
[mania].” It is clear that early life stress can have a life-
long impact on neurochemistry, endocrine responsivity
and behavior, and adult studies have shown that early
manic episodes are more likely to be triggered by stress-
ful life events than later manic episodes [77], all of
which indicates the potential value of working with chil-
dren and adolescents to manage stress and trauma.
Stress can include anything from the expressed emotion
of family members, peers, and teachers, to hypercritical-
ity, to sexual abuse. Unfortunately, Fristad explained,
particularly given the apparently strong genetic compo-
nent of BP, parents who themselves have the disorder
are at increased risk for being less attentive, less active,
more over-protective, and more tense, which can create
stress and trauma for their children.
Miklowitz presented data from several adult studies
[78], including one that compared the effectiveness of
each of FFT, IRST, CBT and psychoeducation in nearly
300 adults with BP [79]. He also discussed four studies
in adolescents [8,80-82], one study of children and ado-
lescents [83], and two studies in children [84]. In each,
the study population was assigned to either psychosocial
treatment(s) or a form of community or collaborative
care. In all studies, the group of patients receiving one
or more of the psychosocial treatment(s) was on average
more likely to have (depending on the particular study’s
design) recovered from an acute episode of BP, experi-
enced improvement in their levels of depression or
mania, received a reduced score on a psychiatric rating
scale, or improved on symptom measures. This data led
Miklowitz to state that, as a rule of thumb, one or more
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cotherapy for early onset BP.” (We are not aware of any
studies that have attempted to discern whether some
psychosocial interventions are more effective in children
who receive the BP label versus those who receive the
SMD label.)
Indeed, Miklowitz stressed that the studies cited above
are just a beginning, and that more research is needed
to better understand how, why, and when various thera-
pies work. In particular, he argued that the goals of each
treatment are not always clear. For example, which
treatments are trying to modify treatment adherence,
which family and peer relationships, and which the abil-
ity to recognize and act on prodromal symptoms? One
barrier to such research is, according to Julie Zito,
NIMH’s failure to prioritize effectiveness research.
Cost is not only an issue in the context of research.
Stephen Crystal et al. have observed that “nonpharmaco-
logical alternatives, which may involve teaching children
problem-solving skills and teaching their parents to
reward positive child behavior, are costly and difficult to
disseminate [70].” Many workshop participants empha-
sized that this cost can effectively reduce the availability
of psychosocial treatments and lead physicians and
families to focus primarily or solely on medication. Psy-
chosocial treatments need to be delivered by trained
professionals, over a period of weeks or months, and are
not always fully covered by medical insurance. Unlike
appointments focused on medication management, psy-
chosocial treatment appointments can last 30-50 min-
utes and may require active participation of multiple
family members. While such treatments may signifi-
cantly improve a child’s symptoms and functioning, and
while in the long term they may provide patients and
their families with tools and strategies to manage and
control symptoms without close supervision, in the
short-to-medium term they are expensive and time con-
suming, requiring energy and commitment from all
involved. NAMI representative Darcy Gruttadaro noted
that “ [while] families want more than medication,
financial incentives and our stressed health care system
favor writing scripts.” To improve the accessibility of
these therapies, health care reform must improve conti-
nuity of care and assure parity between mental health
and medical services. These improvements are especially
important for this difficult-to-treat population, regard-
l e s so ft h ed i a g n o s t i cl a b e l sw ec o n c l u d ea r em o s t
helpful.
Concluding observations
Children and families can suffer terribly as a result of
the serious disturbances in children’s moods and beha-
viors described here. Because moods and behaviors are
distributed continuously in a population (without clean
breaks between normal enough to leave alone and atypi-
cal enough to warrant intervention), both over- and
under-diagnosis are likely problems, although we did
not pursue these problems at this workshop. Instead, we
focused on the controversies surrounding what “actual”
BP looks like in children.
In the mid-1990s, researchers led by Joseph Bieder-
man and Barbara Geller re-described the syndrome of
mania, key to any BP diagnosis. As a result, children
who exhibit, in the case of Geller et al., primarily rapidly
cycling elevated/expansive and/or grandiose mood, or in
the case of Beiderman et al., primarily chronic irritable
mood, have received a diagnosis of BP. These concep-
tualizations of the disorder, in combination with other
social and clinical factors, have fueled a significant
increase in the number of children diagnosed with and
treated for BP. Insofar as everyone agrees that some
fraction of these children warrant the BP diagnosis, an
increase in diagnostic rates is a good thing. The debate
is about how large that fraction is.
Recently, Leibenluft and colleagues have proposed that
many children currently diagnosed with BP may be bet-
ter thought of as exhibiting a syndrome they call SMD.
In addition, other researchers and clinicians have argued
that a BP diagnosis may blind physicians to or mask the
presence of disorders such as severe ADHD, CD, ODD,
PTSD, PDD or some autism spectrum disorders. This
year, the committee responsible for writing the next
iteration of the DSM proposed the addition of a new
childhood disorder to be called Temper Dysregulation
Disorder with Dysphoria, which is based on Leibenluft
et al.’s description of the SMD syndrome.
B a s e do no u rr e a d i n gi nt h eliterature and discussion
at our 2-day workshop, we (the non-psychiatrist
authors) were persuaded that the BP label may fit poorly
many (quantification is difficult) of the children who
have received it over the last decade. We were also per-
suaded that, when DSM IV’s criteria for BP are strictly
applied to children, and psychiatrists revisit the diagno-
sis and treatment plan periodically, the results can be
potentially life-saving and may reduce years of suffering
for the child and family. Clearly, more research is
needed to improve our understanding of the best way to
conceptualize the relationships among the different clus-
ters of symptoms that over the last 15 years increasingly
have been captured with the label BP. DSM V appears
to be addressing this challenge.
We understand that greater nosological clarity may be
difficult to achieve, and that an ill-fitting diagnosis can
sometimes be more helpful to children, families, and
researchers than no diagnosis at all. It is a deeply regret-
table feature of our current mental health and educa-
tional systems that some DSM diagnoses are better than
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and services they so desperately need.
Additional clinician training may also be needed.
Symptom checklists cannot substitute for thorough eva-
luations. Current training practices, as well as reimbur-
sement policies, may leave some child and adolescent
psychiatrists unable to deliver the “biopsychosocial” care
that so many agree is the gold standard. In addition to
funds for research and training, clinical and educational
resources must be available to these children and their
families to relieve immediate stress and to work towards
long-term recovery, symptom remission, and reduced
impairment. These resources represent a significant
financial burden that cannot be borne by families alone.
Given the evolving state of the research, physicians
making a BP diagnosis or treating children with a BP
diagnosis must remain apprised of the debates and fol-
low the AACAP practice parameter’sr e c o m m e n d a t i o n
to revisit the diagnosis and treatment plan at regular
intervals. Though we appreciate the concern regarding
“truth dumping” (where a physician shares an over-
whelming number of partial facts with a patient), that
concern should not prevent physicians from being hon-
est with families. Although it may initially be distressing
for patients and their families to hear that a diagnosis is
not universally accepted and that treatment responses
are debated, providing a false sense of certainty under-
mines the respect for persons necessary in the physi-
cian-patient relationship. Moreover, it may cause
confusion and disillusionment in the future, if the diag-
nosis is revised or if treatment recommendations are
altered.
If physicians are to fulfill their ethical obligation to
facilitate truly informed consent, they must be forth-
coming with families about the relevant uncertainties
and complexities. This may not be easy, but it is essen-
tial. No one should be surprised that in such a massively
complex arena of inquiry, there is uncertainty and dis-
agreement even among the most well intentioned and
well informed professionals.
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